For many people, lack of insurance coverage , steep copays, and other factors can make these medications, known as GLP-1 or GIP/GLP-1 receptor agonists , difficult to access
Given the intractable pediatric obesity epidemic and associated rise in type 2 diabetes in youth, made worse by the COVID-19 pandemic related shutdowns and disruptions in opportunities for exercise and play in youth, this new class of medications will certainly benefit children with morbid obesity and type 2 diabetes
The deviation-model assessment did not demonstrate significant deviation among the current NMA (Additional file: Fig
We believe in transparency, clean ingredients, and the power of intentional living
A licensed broker or a State Health Insurance Assistance Program (SHIP) counselor in Washington can help you navigate that process at no cost
The weight loss and diabetes drug market is being reshaped by GLP-1-based therapies, led by Novo Nordisk's Ozempic Registered and Wegovy Registered and Eli Lilly's Mounjaro Registered (Zepbound for obesity)
